TUBB2A and systemic lupus erythematosus: For systemic lupus erythematosus (SLE), another uncharacterized disease, TUBB2A was predicted as an activatory target, consistent with its significant downregulation in patients with SLE (P=5.0×10-5) (Zhang et al. 2019).